Business
Rallybio Appoints Wendy K. Chung, M.D., Ph.D., to Its Board of Directors
NEW HAVEN, Conn.--(BUSINESS WIRE)-- Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the
About this update from Rallybio Corporation
[{"type":"text","content":" NEW HAVEN, Conn.--(BUSINESS WIRE)--\nRallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that it has appointed Wendy K. Chung, M.D., Ph.D., to its Board of Directors.\n\n“Wendy is a tremendous addition to our Board of Directors. Her extensive clinical experience and deep scientific expertise will be a valued asset as we continue to advance our current product portfolio as well as bring additional candidates into our pipeline. We look forward to learning from her expertise and insights,” said Martin Mackay, Ph.D., Chairman and Chief Executive Officer at Rallybio. “On behalf of our directors, I am pleased to welcome Wendy to Rallybio’s Board.”\n\n“As a clinician, I have seen firsthand the significant unmet need for transformative therapies for patients with severe and rare diseases. I look forward to utilizing my scientific background and prior experience to contribute to the Board and the work of the Rallybio team as the Company continues to advance their current portfolio of product candidates and evaluate potential assets for their pipeline,” said Dr. Chung.\n\nAbout Dr. Chung\n\nDr. Chung is an accomplished leader in the diagnosis and treatment of rare diseases. She is a board certified clinical and molecular geneticist with more than 20 years of experience in human genetic research. Currently, Dr. Chung is the Kennedy Family Professor of Pediatrics and Medicine at Columbia University Irving Medical Center and the Director of Precision Medicine Resource for the Irving Institute for Translational Research at Columbia University. She has authored over 600 peer reviewed papers and 75 reviews and chapters in medical texts. Dr. Chung currently serves as a member of the Board of Directors of Prime Medicine. In addition, Dr. Chung is a member of the Scientific Advisory Board for Sage Bionetworks, Taysha, Helix, and Regeneron Genetics Center. Dr. Chung holds a Bachelor of Arts in Biochemistry and Economics from Cornell University, a Doctor of Medicine from Cornell University Medical College, a Doctor of Philosophy in Genetics from The Rockefeller University.\n\nAbout Rallybio\n\nRallybio is a clinical-stage biotechnology company committed to identifying and accele...